Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test (Review)Copyright
Data collection and analysis
Two review authors independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found; therefore no data were analysed.
Main results
The search identified 813 references on MEDLINE, 418 on EMBASE, 22 on CINAHL, 666 on PubMed, 291 on PsycINFO and 145 on CENTRAL. When all references were imported into EndNote and duplications were removed, 1348 references remained. Initial screening of titles and abstracts of these references revealed that 42 references were potentially eligible for this review. After reading the full-text versions, we identified no relevant trials comparing hrHPV and cytology testing versus cytology testing alone for detecting residual or recurrent disease during follow-up to LLETZ treatment of adult women with CIN.
We found no evidence on the effects of hrHPV and cytology testing on residual or recurrent CIN2 or higher lesions, anxiety and psychosexual morbidity outcomes in women undergoing colposcopy and treatment for CIN.
Authors' conclusions
We found no evidence from RCTs to inform decisions about the best surveillance strategy for women following treatment for CIN. A prognostic systematic review is needed to investigate the risk of developing recurrent cervical intraepithelial neoplasia 2+ (CIN2+) in women with a positive hrHPV test after large loop excision of the transformation zone (LLETZ) treatment.
P L A I N L A N G U A G E S U M M A R Y

Follow-up strategies for women following treatment for CIN: Impact of HPV testing Background
It is widely accepted that infection with high-risk human papillomavirus (hrHPV) is associated with development of precancerous changes, namely, cervical intraepithelial neoplasia (CIN) and cervical cancer. It is also accepted that women who develop high-grade CIN and subsequently receive treatment with a procedure called large loop excision of the transformation zone (LLETZ), which uses a wire loop to remove abnormal cells, are at greater risk for developing further CIN than women who have never had CIN. Therefore, these women need regular follow-up assessment to detect additional abnormalities.
Main findings
We searched for randomised control trials (RCTs) that compared follow-up management strategies following LLETZ treatment for CIN. We checked 1348 titles and abstracts of potentially relevant references, but we identified no randomised controlled trials (RCTs) that met our inclusion criteria. We identified trials of interest, but they were deemed not relevant because of their focus on diagnostic outcomes and examination of how sensitive tests are, rather than on the effects of different follow-up strategies on long-term outcomes. Currently no evidence indicates whether hrHPV post-treatment testing is better or worse in terms of important long-term clinical outcomes. This review highlights the need for good quality trials in this area that do not focus solely on the diagnostic accuracy of testing.
Conclusion
We found no evidence from RCTs to inform decisions about the best surveillance strategy following treatment for CIN. A prognostic systematic review is needed to investigate the risks and benefits of different follow-up strategies for women after LLETZ treatment.
fore cervical cancer develops, cervical cells undergo changes and become abnormal. These abnormalities are called cervical intraepithelial neoplasia (CIN) and are associated with increased risk of subsequent invasive cancer of the cervix (Pinto 2000). Cervical cancer is the second most common cancer among women up to 65 years of age and is the most frequent cause of death from gynaecological cancers worldwide. A woman's risk of developing cervical cancer by age 65 ranges from 0.69% in developed countries to 1.38% in developing countries (GLOBOCAN 2008) . In Europe, about 60% of women with cervical cancer were alive five years after diagnosis (EUROCARE 2003) . It is widely accepted that infection with onogenic high-risk human papillomavirus (hrHPV) is associated with development of CIN and cancer (Galaal 2011; McCredie 2008; Pinto 2000) . Strong epidemiological evidence demonstrates that the major risk factor for development of preinvasive or invasive carcinoma of the cervix is HPV infection (Brisson 1994) . Increased exposure to hrHPV is related to other known risk factors including high parity, increasing numbers of sexual partners, young age at first intercourse, low socioeconomic status and a history of smoking (Brisson 1994; Schiffman 1993).
Description of the intervention
Large loop excision of the transformation zone (LLETZ), also described as the loop electrosurgical excision procedure (LEEP), is highly effective in the treatment of patients with CIN and early invasive disease (Federation of Gynecology and Obstetrics (FIGO) stage 1A1). However, following treatment, 4% to 17% of women have CIN2 or greater as the result of residual (persistent CIN confirmed on biopsy within two years of follow-up) or recurrent disease (CIN identified after two years of negative cytology) (Alvarez 1994; Bollen 1999; Jain 2001; Mitchell 1998). Previous studies have shown that risk of residual or recurrent disease is consistently associated with large lesion size before LLETZ, endocervical extension of the disease and incomplete excision of the lesion (Brockmeyer AD 2003; Costa 2003; Houfflin Debarge 2003). However, even women with clear excision margins are at risk for disease recurrence (Paraskevaidis E 2000). In addition, the risk of developing invasive cancer after treatment for high-grade CIN is five times higher than in the general population (Brown 1991; Souter 2006). This was the justification for closer surveillance of these groups of women with annual cytology and colposcopy follow-up for 10 years after treatment (Jones 2011). Therefore, women treated for CIN2 or CIN3 were recommended to have cytological follow-up six months and 12 months after treatment, and annual cytology for the next nine years, before returning to screening at the routine interval (Luesley 2010). Numerous studies have suggested that hrHPV testing is more sensitive than cytology and has negative predictive value of almost 100% for detection of CIN2+ (Bias 2009; Kocken 2012; Kreimer 2006). It is suggested that "double-negative" HPV DNA and cervical cytology testing indicate higher prognostic assurance against risk of future CIN3 than three subsequent negative conventional cervical cytology tests and may safely allow three-year or longer screening intervals for such low-risk women (Lörincz 2003) . Since April 2012 the algorithm in the UK is to have 'HPV test of cure' six months after treatment for CIN. The HPV test of cure uses a woman's hrHPV status to assess her risk of having residual or recurrent disease after treatment for CIN (NHSCSP 2011) . It is performed six months after treatment and includes both cytology and HPV testing. Women whose cytology samples are reported as high-grade dyskaryosis or worse are returned to colposcopy without undergoing an HPV test, then are followed up according to national guidelines (Arbyn 2007). All other women are treated according to their hrHPV test result: Those who are hrHPV-positive at test of cure are referred back to colposcopy, whereas those who are hrHPV-negative are recalled in three years and can revert to routine recall thereafter (NHSCSP 2011).
How the intervention might work
Oncogenic high-risk human papillomavirus (hrHPV), the causative agent of cervical cancer and its precursor lesions, is present in up to one-third of women following LLETZ and is associated with increased risk of disease recurrence (Costa 2003; Paraskevaidis E 2000). Therefore, hrHPV testing may serve as a surveillance tool for identifying women at high risk of recurrence. High-risk HPV persistence after high-grade CIN removal may be associated with residual lesions or risk of disease recurrence (Sarian 2004). High-risk HPV testing will enable us to identify women at increased risk of recurrent CIN, and therefore will allow us to offer closer surveillance and early treatment when indicated. An advantage of hrHPV test of cure is improved sensitivity for the detection of residual recurrent disease; also women whose followup samples test negative for hrHPV need only return for two or three routine cytology tests (depending on their age) during the decade after treatment instead of requiring a minimum of 10 years of annual follow-up cytology, again reflecting the negative predictive value of a negative hrHPV test (NHSCSP 2011). In addition, post-treatment hrHPV testing could be useful in the follow-up of patients after completion of treatment. In cases of negative post-treatment hrHPV testing, the frequency of followup could be reduced, particularly among patients with free margins (Houfflin Debarge 2003).
Why it is important to do this review
Following excision of CIN using LLETZ, post-treatment CIN rates of 4% to 17% have been reported (Alvarez 1994; Bollen 1999; Jain 2001; Mitchell 1998). Therefore, follow-up after local treatment for CIN is mandatory because of the late occurrence of cervical cancer over a period of 20 years (Ghaem-Maghami 2007; Soutter 1997). To prevent cervical cancer, early detection of treat-ment failure is important. It has been suggested that persistence of hrHPV represents an independent risk factor for recurrent disease and constitutes the basis for introducing hrHPV testing in patients treated for high-grade CIN (Fallani 2008; Nam 2009). However, this policy of reducing the follow-up interval among patients with double-negative cytology and hrHPV has not been directly compared with cytological follow-up six months and 12 months after treatment and annual cytology for the next nine years before a return to screening at the routine interval. Therefore, a systematic review of current evidence is needed for a reliable evaluation of potential benefits and risks of these surveillance policies.
O B J E C T I V E S
• To evaluate the effectiveness and safety of hrHPV testing after large loop excision of the transformation zone (LLETZ) treatment.
• To determine optimal follow-up strategies following LLETZ treatment according to hrHPV status.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adult women (18 years of age or older) undergoing LLETZ for the treatment of CIN.
Types of interventions
Intervention Post-treatment hrHPV testing. Control Conventional cervical screening with a Papanicolaou test (Pap smear).
Types of outcome measures Primary outcomes
• Residual or recurrent, or both, CIN2 or higher lesion.
Secondary outcomes
• Anxiety, measured using a validated scale.
• Pyschosexual scores, measured using a validated scale.
Search methods for identification of studies
Papers in all languages were sought and translations carried out when necessary.
Electronic searches
See Cochrane Gynaecological Cancer Group methods used in reviews. We searched the following electronic databases.
• The Cochrane Gynaecological Cancer Collaborative Review Group's Trial Register.
• The Cochrane Central Register of Controlled Trials (CENTRAL) to August 2013.
• MEDLINE to August 2013.
• EMBASE to August 2013. MEDLINE, EMBASE, CENTRAL, CINAHL and PsycINFO search strategies based on terms related to the review topic are presented in Appendix 1, Appendix 2 and Appendix 3, respectively. All relevant articles identified were found on PubMed; using the 'Related articles' feature, we performed a further search for newly published articles.
Searching other resources
Unpublished and grey literature
We searched metaRegister (http://www.controlled-trials.com/ rct), Physicians Data Query (http://www.nci.nih.gov), http:/ /www.clinicaltrials.gov and http://www.cancer.gov/clinicaltrials for ongoing trials. We searched conference proceedings and abstracts through ZE-TOC (http://zetoc.mimas.ac.uk) and WorldCat Dissertations. Handsearching We handsearched the citation lists of included studies, key textbooks and previous systematic reviews and contacted experts in the field to identify further reports of trials. We handsearched reports of conferences in the following sources.
• Gynecologic Oncology (Annual Meeting of the Society of Gynecologic Oncology).
• We also searched the following websites.
• British Gynaecological Cancer Society (www.bgcs.org.uk).
• European Society of Gynaecological Oncology ( www.esgo.org).
• Society of Gynecologic Oncology (www.sgo.org).
Correspondence
We planned to contact authors of relevant trials to clarify information on the quality of randomisation and other details.
Data collection and analysis
We downloaded to the reference management database, EndNote, all titles and abstracts retrieved by electronic searching. We removed duplicates, and the remaining references were examined independently by two review authors (EH, KG). These two review authors screened the references by titles and abstracts and eliminated references that were not related to the research question. When both review authors agreed on exclusion of a reference, no further action was taken. When one or both of the review authors determined that the article may have been eligible for inclusion, we obtained the full-text article. Each review author then independently decided whether these studies were eligible. We resolved disagreements about inclusion by discussion. We contacted study authors when information required for a decision on whether a study was eligible was missing. We were not blinded to article titles or authors nor to journal titles. All references were ultimately excluded, as they did not meet the inclusion criteria. We identified no ongoing randomised controlled trials that met our inclusion criteria through our searches of the grey literature. In future updates of this review, we will employ the methods outlined under Differences between protocol and review.
R E S U L T S Description of studies Results of the search
Through our searches, we identified 813 references on MED-LINE, 418 on EMBASE, 22 on CINAHL, 666 on PubMed, 291 on PsycINFO and 145 on CENTRAL. When all references had been imported into EndNote and all duplications removed, 1348 references remained. Initial screenings of titles and abstracts of these references revealed that 42 references were potentially eligible for inclusion in this review. After reading the full-text versions, we identified no relevant studies.
Included studies
No trials met the inclusion criteria.
Excluded studies
A total of 42 references were excluded from the review; 37 were excluded because they were not RCTs ( No consensus has been reached regarding the duration of posttreatment surveillance, but patients treated for cervical intraepithelial neoplasia (CIN) are at increased risk for cervical cancer as compared with the general population for at least 10 years after treatment (Leguevaque 2010). A test that predicts successful outcomes after treatment for CIN allowing reduction in the followup period would be particularly helpful. Several studies suggest that follow-up after treatment should combine the high-risk human papillomavirus (hrHPV) test with conventional cytology, as it identifies patients with a high risk of recurrence. Women are managed according to their hrHPV test result: Those who are hrHPV-positive at test of cure are referred back to colposcopy, whereas those who are hrHPV-negative are recalled in three years and can revert to routine recall thereafter (Leguevaque 2010). This review identified no studies that compared post-treatment hrHPV testing with cytology 'test of cure' versus post-treatment cytological follow-up at six months and 12 months after treatment, and annual cytology for the next nine years before a return to screening at the routine interval. No randomised trials have directly compared the long-term outcomes of two follow-up management strategies. However, several studies have evaluated the risk of persistent recurrence of CIN after treatment. No studies have compared long-term outcomes (high-grade CIN (CIN2+) and cervical cancer rates) of these two treatment strategies. Studies have found similar short-term high-grade CIN rates in women who underwent hrHPV testing as part of their follow-up strategy. However, this would be expected, as in a randomised study, posttreatment groups should be well balanced and the actual treatment (large loop excision of the transformation zone (LLETZ)) the same in both groups, hence similar high-grade residual disease. A prognostic review, looking at the risk of developing recurrent high-grade CIN and cervical cancer among women with a positive hrHPV test after LLETZ treatment, would be valuable.
Quality of the evidence
No studies met the inclusion criteria for this review, so no evidence is available for assessment.
Potential biases in the review process
A comprehensive search including a thorough search of the grey literature was performed; all studies were sifted and data extracted independently by at least two review authors. The review was restricted to randomised controlled trials (RCTs), which provide the strongest level of available evidence. Hence we made every attempt to minimise bias in the review process. The greatest threat to the validity of this review is likely to be the possibility of publication bias (i.e. studies that did not find the treatment to have been effective may not have been published). We were unable to assess this possibility, as we found no eligible trials.
Agreements and disagreements with other studies or reviews
We found no studies directly comparing the two modalities of follow-up management strategies after treatment for CIN. Clinical factors for recurrence, including the presence of positive endocervical margins, remain an important factor. We identified no studies that reported on anxiety or psychosexual outcomes. However, we identified one relevant prospective study (Kocken 2011) that reported on disease recurrence in terms of positive versus negative hrHPV results in women who underwent hrHPV testing with cytology. Women with negative results for co-testing (cytology and hrHPV) had five-year risk of CIN grade 2+ of 1.0% (95% confidence interval (CI) 0.2 to 4.6) and 10-year risk of 3.6% (95% CI 1.1 to 10.7). The five-year risk of CIN grade 3 or higher was 0.0% (95% CI 0.0 to 3.0), and the 10-year risk was 0.0% (95% CI 0.0 to 5.3). We did identify two RCTs (Bias 2009; Kreimer 2006) (including 552 women in total), but they did not meet our inclusion criteria because of their focus on diagnostic outcomes and examination of the sensitivity/specificity of hrHPV testing for residual disease. These trials found no differences in risk of residual disease at two years between women who received hrHPV testing with cytology and those who received cytology alone. This would be expected, as the intervention to prevent CIN2+ was the same (LLETZ), thus demonstrating that the comparison groups were well balanced. These studies also suggest that an addedhrHPV test may confer an advantage over the cervical smear test alone, as data suggest that women with negative hrHPV testing during follow-up after treatment for high-grade CIN are at low risk for CIN2+ and could return to a routine threeyearly screening programme. Data on anxiety and psychosexual outcomes were not reported in either trial.
A U T H O R S ' C O N C L U S I O N S Implications for practice
We found no current evidence from RCTs to guide optimal followup strategies in the treatment of women with CIN2+.
A prognostic review investigating the risk of developing recurrent cervical intraepithelial neoplasia 2+ (CIN2+) in women with a positive hrHPV test after LLETZ treatment is required.
Implications for research
• With the move to primary hrHPV screening in several countries, further studies comparing primary hrHPV testing post treatment for CIN versus hrHPV and cytology are needed to determine the optimal follow-up strategy. Primary hrHPV screening has greater sensitivity compared with cytology (average 27%) but has lower specificity (average 8%) (Franco 2003). Follow-up strategies incorporating hrHPV testing alone would allow the detection of higher percentages of women with recurrent abnormalities, as hrHPV testing has higher sensitivity compared with cytology alone. In many countries hrHPV testing is used in both screening and follow-up strategies. Therefore we would recommend that future studies should be designed to compare hrHPV testing alone versus hrHPV and cytology testing in the follow-up treatment for high-grade CIN. This would allow us to evaluate the effects of hrHPV testing added to the current follow-up strategy.
• Ideally, well-designed large multi-centre (ideally multinational) RCTs addressing hrHPV testing in the follow-up of treatment for CIN2+ are needed. Trial authors should follow the CONSORT statement checklist in providing complete and clear documentation (Hopewell 2008).
• Data on disease recurrence ideally should include time-toevent outcomes when results can be presented in six-month intervals.
• Trials are needed to evaluate interventions introducing anxiety and psychosexual outcomes in relation to hrHPV testing.
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The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group. A retrospective study, which included 120 women treated for CIN2+. Follow-up visits were scheduled every 3 to 6 months the first year, then annually. During follow-up, specimens were tested for persistence of hrHPV. The correlation between persistence of hrHPV and residual/recurrent disease was calculated Reason for exclusion: not an RCT; no comparison with cytology Bar-Am 2003 A prospective study, which included 67 women with CIN2+ who underwent cone biopsy. All women had follow-up for 3 years with a 6-month interval visit and another for 2 years annually. Every follow-up visit, an hrHPV test and a cytology test were performed. Correlation between cytology and hrHPV results was calculated, and the hrHPV clearance rate during the follow-up period is shown Reason for exclusion: not an RCT
C H A R A C T E R I S T I C S O F S T U D I E S
Bekkers 2002
A prospective study, which included 90 women treated for CIN2+ with LLETZ. Two liquid-based cervical scrapes were taken after 3 months and 6 months, and cytology was taken at every follow-up visit (median cytological follow-up of 32 months (24 to 47 months)). hrHPV testing was performed at liquid-based cervical scrapes. Performance of hrHPV testing at 3 months and 6 months after LLETZ and performance of conventional cytology at 3 months and 6 months after LLETZ were calculated using the gold standard (cytology follow-up and colposcopy after 6 months) Reason for exclusion: not an RCT Bias 2009 RCT, which included 204 women diagnosed with high-grade cervical intraepithelial neoplasia lesions (CIN2-3) who were treated with large loop excision of the transformation zone (LLETZ), cold-knife conisation or laser conisation. However, the 2 modalities of follow-up management strategies after treatment (Continued)
for CIN were not compared Bollen 1999 A prospective study, which included 43 women with abnormal cytology after treatment for cervical dysplasia. All women were referred for colposcopy, and before colposcopy HPV tests were done and biopsies were taken for histological examination. hrHPV test results were compared with histological results, and test parameters were calculated Reason for exclusion: not an RCT; participants did not meet our inclusion criteria
Brismar 2009 A prospective observational study, which included 90 women who underwent cytological testing and hrHPV genotyping at the follow-up visit after conisation. One arm (33) had follow-up within 12 months, and the other arm (57) had follow-up after 12 months. Cone specimens were genotyped retrospectively. HPV types before and after conisation were compared and correlated with residual/recurrent disease Reason for exclusion: not an RCT; test results after 6 months of follow-up not specified A prospective follow-up study, which included 52 women treated for high-grade CIN with laser conisation. Follow-up was scheduled at 3, 6 and 12 months after treatment with cytology and hrHPV testing on selfcollected urine and cervical scrapes. Diagnostic accuracy and predictive values for treatment failure were evaluated for both urinary and cervical HPV testing and for follow-up cytology 18. #14 or #15 or #16 or #17 19. #5 and #13 and #18
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
All references were ultimately excluded, as they clearly did not meet the inclusion criteria. We identified no ongoing randomised controlled trials that met our inclusion criteria from our searches of the grey literature. In future updates of the review, we will employ the following methods.
Copies of the full text of relevant references will be obtained, as outlined in the Methods section. Eligibility of retrieved papers will be assessed independently by two review authors. Disagreements will be resolved by discussion between the two review authors. Reasons for exclusion will be documented.
Data extraction and management
We will abstract data for the included studies as recommended in Chapter 7 of theCochrane Handbook for Systematic Reviews of Interventions version 5.1 (Higgins 2011). Two review authors will extract data independently and will include the following.
• Study author, year of publication and journal citation (including language).
• Country.
• Setting.
• Inclusion and exclusion criteria.
• Study design, methodology.
• Study population.
• Total number enrolled.
• Participant characteristics. ⋄ Age. ⋄ Race. ⋄ Co-morbidities. ⋄ Previous treatment.
• CIN details at diagnosis.
• CIN2, CIN3 details.
• Intervention details.
• Post-treatment HPV testing in combination with cytology testing ± HPV typing.
• Criteria for referral to colposcopy.
• Comparison details.
• Conventional cervical screening with Pap smear.
• Risk of bias in study (see below).
• Duration of follow-up and follow-up intervals.
• Outcomes: See above.
• For each outcome: outcome definition (with diagnostic criteria if relevant).
• Unit of measurement (if relevant).
• For scales: upper and lower limits, and whether high or low score is good.
• Results: number of participants allocated to each intervention group.
• For each outcome of interest: sample size; missing participants; reasons for loss to follow-up.
We will extract data on outcomes as below.
• For time-to-event (developing recurrent CIN2 or higher lesion) data, we will extract the log of the hazard ratio [log(HR)] and its standard error from trial reports (if these are not reported, we will attempt to estimate them from other reported statistics using the methods of Parmar 1998).
• For dichotomous outcomes (e.g. developing recurrent CIN2 or higher lesion if not expressed as time-to-event data), we will extract the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint (e.g. residual/recurrent disease) to estimate a risk ratio (RR).
• For continuous outcomes (e.g. anxiety, psychosexual scores), we will extract the final value and the standard deviation of the outcome of interest and the number of participants assessed at endpoint in each treatment arm at the end of follow-up to estimate the mean difference (if trials measured outcomes on the same scale) or the standardised mean difference (if trials measured outcomes on different scales) between treatment arms and its standard error.
When possible, all extracted data will be those relevant to an intention-to-treat analysis in which participants are analysed in the groups to which they were assigned. We will note the time points at which outcomes were collected and reported. Data will be abstracted independently by two review authors (EH, KG) onto a data abstraction form specially designed for the review. We will resolve differences between review authors by discussion or by appeal to a third review author (AB).
Assessment of risk of bias in included studies
We will assess the risk of bias of included RCTs in accordance with guidelines provided in the Cochrane Handbook for Systematic Reviews of Interventions using the tool of The Cochrane Collaboration and the criteria specified in Chapter 8 (Higgins 2011). This will include assessment of the following.
• Sequence generation.
• Allocation concealment.
• Blinding (will be restricted to blinding of outcome assessors, as not possible to blind participants and healthcare providers to interventions).
• Incomplete outcome data.
• We will record the proportion of participants whose outcomes are not reported at the end of the study. We will code the satisfactory level of loss to follow-up for each outcome as follows.
⋄ Yes, if fewer than 20% of participants are lost to follow-up and reasons for loss to follow-up are similar in both treatment arms.
⋄ No, if more than 20% of participants are lost to follow-up or reasons for loss to follow-up are different between treatment arms. ⋄ Unclear, if loss to follow-up is not reported.
• Selective reporting of outcomes.
• Other possible sources of bias.
The risk of bias tool will be applied independently by two review authors (EH, KG) and differences will be resolved by discussion or by appeal to a third review author (AB). Results will be summarised in both a risk of bias graph and a risk of bias summary. Results of meta-analyses will be interpreted in the light of findings with respect to risk of bias.
Measures of treatment effect
We will use the following measures of the effects of treatment.
• For time-to-event data, we will use the hazard ratio (HR), if possible.
• For dichotomous outcomes, we will use the risk ratio (RR).
• For continuous outcomes, we will use the mean difference between treatment arms.
Dealing with missing data
We will not impute missing outcome data for any of the outcomes.
Assessment of heterogeneity
We will assess heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage of heterogeneity between trials that cannot be ascribed to sampling variation (Higgins 2003), by a formal statistical test of the significance of heterogeneity (Deeks 2001) and, if possible, by subgroup analyses (Subgroup analysis and investigation of heterogeneity). If evidence suggests substantial heterogeneity, possible reasons for this will be investigated and reported.
Assessment of reporting biases
We will examine funnel plots corresponding to meta-analyses of the primary outcome to assess the potential for small-study effects such as publication bias.
Data synthesis
If sufficient clinically similar trials are available, their results will be pooled in meta-analyses.
• For time-to-event data, we will pool HRs using the generic inverse variance facility of RevMan 5.
• For dichotomous outcomes, we will calculate the RR for each trial and will pool the RRs.
• For continuous outcomes, we will pool mean differences between treatment arms at the end of follow-up if all trials measured the outcome on the same scale; otherwise we will pool standardised mean differences.
We will use random-effects models with inverse variance weighting for all meta-analyses (DerSimonian 1986).
Sensitivity analysis
We will perform sensitivity analyses excluding studies at high risk of bias.
